Fate's closely watched stem cell-derived NK program raises red flag over durability of response

Kyle Blankenship

At the cutting edge of oncology research, biotechs like Fate Therapeutics are looking for ways to craft next-gen cell therapies without relying on patients’ own …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Fate's closely watched stem cell-derived NK program raises red flag over durability of response

Kyle Blankenship

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Deputy FDA chief mulls shaking up PDUFA reauthorization structure

Updated: Novo Nordisk CEO to step down amid stock decline, timeline for successor unknown

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

Lower attendance at cell and gene therapy conference mirrors challenged industry

FDA poses efficacy, safety questions over four cancer drugs ahead of two-day adcomm

Novo Nordisk’s global obesity leader is moving on; Flagship biotech gets CEO from Scholar Rock

Fate's close­ly watched stem cell-de­rived NK pro­gram rais­es red flag over dura­bil­i­ty of re­sponse

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Fate's closely watched stem cell-derived NK program raises red flag over durability of response